Kolexia
Leblond Véronique Hématologie
Leblond Véronique
Hématologie
Hôpital Pitie Salpetriere
Paris, France
436 Activités
2 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Leucémies Leucémie chronique lymphocytaire à cellules B Macroglobulinémie de Waldenström Leucémie lymphoïde Lymphomes Maladie résiduelle Syndromes lymphoprolifératifs Lymphome B Maladie de Hodgkin

Collaborateurs

Voir plus
Choquet Sylvain
Choquet Sylvain
Hôpital Pitie Salpetriere, Paris, France
Lepretre Stephane
Lepretre Stephane
Centre Henri-Becquerel, Rouen, France
Tournilhac Olivier
Tournilhac Olivier
Hôpital Estaing, Clermont-Ferrand, France
Cymbalista Florence
Cymbalista Florence
Hôpital Avicenne, Bobigny, France

Industries

Voir plus
AstraZeneca
35 collaboration(s)
Dernière en 2023
Edimark
28 collaboration(s)
Dernière en 2023
Janssen
24 collaboration(s)
Dernière en 2023
Abbvie
21 collaboration(s)
Dernière en 2023

Dernières activités

Voir plus
Final results on effectiveness and safety of Ibrutinib in patients with chronic lymphocytic leukemia from the non-interventional FIRE study.
Annals of hematology   06 mars 2024
Circulating tumor cells in Waldenström macroglobulinemia.
Leukemia   09 février 2024
Biomarker analysis of the ASPEN study comparing zanubrutinib to ibrutinib in patients with Waldenström Macroglobulinemia.
Blood advances   05 février 2024
Efficacy of First Line DRC +/- Bortezomib for Patients With Waldenström's Macroglobulinemia: Efficacy of First Line Dexamethasone, Rituximab and Cyclophosphamide (DRC) +/- Bortezomib for Patients With Waldenström's Macroglobulinemia
Essai Clinique (University of Ulm)   29 novembre 2023
Minimal Residual Disease-Guided Combination of Ibrutinib and Venetoclax Compared to FCR in Untreated Patients with CLL of Intermediate Risk : Interim Results of MRD Kinetics in the Eradic Trial from the Filo Group
65th ASH Annual Meeting Abstracts   02 novembre 2023
Lenalidomide Consolidation Improves Measurable Residual Disease (MRD) Rates and Progression Free Survival in Patients with Chronic Lymphocytic Leukemia Following Initial FCR Chemotherapy - Final Analysis of CLL6 Residuum Study of the Australian Leukaemia and Lymphoma Group (ALLG) and the French Innovative Leukemia Organization (FILO)
65th ASH Annual Meeting Abstracts   02 novembre 2023
RemodelWM3: An Open Label Non-randomized Phase II Study Exploring "Chemo-free " Treatment Association With Idelalisib + Obinutuzumab in Patient With Relapsed/Refractory Waldenstrom's Macroglobulinemia
Essai Clinique (French Innovative Leukemia Organisation)   28 août 2023
Waldenström's macroglobulinaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
Annals of oncology : official journal of the European Society for Medical Oncology   07 août 2023
Waldenström's macroglobulinaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
Annals of oncology : official journal of the European Society for Medical Oncology   07 août 2023
A fixed-duration immunochemotherapy approach in CLL: 5.5-year results from the phase 2 ICLL-07 FILO trial.
Blood advances   28 juillet 2023